Pazonat (Pazopanib) 400 mg
Pazonat 400 (Pazopanib 400 mg) is a tyrosine kinase inhibitor (TKI) used to treat specific types of cancer.
Manufacturer: Natco Pharma (India). A generic equivalent of Votrient.
Mechanism ("Starving the Tumor"):
Pazopanib is an angiogenesis inhibitor. Tumors need a blood supply to grow. This medication stops the formation of new blood vessels that feed the cancer cells. By cutting off the nutrient and oxygen supply, it effectively "starves" the tumor, halting its growth.
✅ Key Benefit: Offers a pill-based treatment option for advanced kidney cancer with proven efficacy.
Indicated for the treatment of adults with:
- 🎗️ Advanced Renal Cell Carcinoma (RCC): Kidney cancer that has spread or relapsed.
- 🦴 Advanced Soft Tissue Sarcoma (STS): For patients who have received prior chemotherapy (specifically for subtypes where efficacy is proven).
Standard Dosage: 800 mg (Two 400 mg tablets) once daily.
⚠️ CRITICAL SAFETY WARNING:
- 🚫 Take on an EMPTY STOMACH only.
- ⏰ Timing: At least 1 hour before or 2 hours after a meal.
- Reason: Taking this drug with food increases absorption dangerously, leading to toxicity.
💊 Do not crush: Swallow tablets whole. Crushing increases the rate of absorption and risk of side effects.
- Severe hepatic impairment.
- Pregnancy and breastfeeding (teratogenic effects).
- Gastrointestinal fistula or severe bleeding risk.
Monitoring is essential:
- 🦁 Hair Depigmentation: Hair color may turn white or grey. This is a common, non-harmful side effect.
- 📉 Hepatotoxicity: Elevated liver enzymes (ALT/AST). Frequent blood tests are mandatory.
- Hypertension: High blood pressure.
- Diarrhea, fatigue.
What Customers Say
No reviews yet
Your review can be the first!